The Neuroprotective Disease-Modifying Potential of Psychotropics in Parkinson's Disease

Tufekci, K. U., Genc, S., & Genc, K. (2011). The Endotoxin-Induced Neuroinflammation Model of Parkinson’s Disease. Parkinson＇s Disease, 2011(), 402-426. https://doi.org/10.4061/2011/487450
Lee, H. M., & Kim, Y. (2016). Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophrenia Research and Treatment, 2016(), 49-60. https://doi.org/10.1155/2016/6378137
Ferrer, I. (2011). Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson’s Disease. Parkinson＇s Disease, 2011(), 637-649. https://doi.org/10.4061/2011/708404
Hisahara, S., & Shimohama, S. (2011). Toxin-Induced and Genetic Animal Models of Parkinson’s Disease. Parkinson＇s Disease, 2011(), 894-907. https://doi.org/10.4061/2011/951709
Teixeira, A. L., Fontenelle, L. F., Lauterbach, E. C., & Starkstein, S. (2012). Neuropsychiatry of Parkinson's Disease. Parkinson＇s Disease, 2012(), 739-740. https://doi.org/10.1155/2012/908943